Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
2014-March Volume 7 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
2014-March Volume 7 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Involvement of conserved tryptophan residues for secretion of TIMP‑2

  • Authors:
    • Tamami Ukaji
    • Yukiko Sasazawa
    • Kazuo Umezawa
    • Siro Simizu
  • View Affiliations / Copyright

    Affiliations: Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Kanagawa 223‑8522, Japan
  • Pages: 631-634
    |
    Published online on: December 23, 2013
       https://doi.org/10.3892/ol.2013.1771
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Tissue inhibitor of metalloproteinases (TIMPs) are endogenous inhibitor proteins of matrix metalloproteinases and contain 12 cysteine residues that are conserved among TIMPs, and which are important for their activity and structure. In the present study, three tryptophan residues conserved among TIMPs were revealed to be important for the secretion of TIMP‑2. Replacement of conserved tryptophan residues in TIMP‑2 with alanine led to a decrease in extracellular TIMP‑2 levels and an increase in intracellular TIMP‑2 levels. Furthermore, wild‑type TIMP‑2 and TIMP‑2 mutated at unconserved tryptophan residues mainly localized in the Golgi apparatus, while TIMP‑2 proteins mutated at conserved tryptophan were mainly observed in the endoplasmic reticulum (ER). This indicated that conserved tryptophan is essential for transporting TIMP‑2 from the ER to Golgi apparatus. These observations suggested that conserved tryptophan residues among the TIMP family of proteins have critical roles for ER‑Golgi transport and subsequent secretion of TIMP‑2.

Introduction

The extracellular matrix (ECM) is a complex network composed of macromolecules, including collagen, hyaluronic acid, fibronectin, proteoglycans and glycoproteins, which presents within all tissues and organs and is necessary for multicellular organisms to maintain cellular function. A number of ECM components are degraded by matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases. MMPs are involved in a number of diseases, including tumor metastasis, rheumatoid arthritis and periodontal disease (1). Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of MMPs and contribute to inhibiting tumorigenesis and subsequent malignant progression by regulating ECM turnover (2–4). TIMPs bind to the active sites of MMPs non-covalently in a 1:1 stoichiometric manner and constitute a family of four proteins (TIMP-1, -2, -3 and -4). Mammalian TIMP family proteins are subdivided into N- and C-terminal subdomains consisting of ~125 and ~65 amino acids, respectively (5). Each domain contains three disulfide bonds formed between the cysteine residues conserved among all four TIMPs, which are important for their activity and structure (6). The N-terminal domain is highly conserved among four human TIMPs and in TIMPs of other species, and acts as a depressant of MMPs and specific a disintegrin and metalloproteinase (ADAM) and a disintegrin and metalloproteinase with thrombospondin motif (ADAMTS) family members, while the C-terminal domain mediates protein-protein interaction (7).

Although the four TIMPs exhibit similar structures, they are expressed in various tissues and have various MMP-inhibitory profiles (5). Among them, TIMP-2 has the unique feature of biphasic regulation of MMPs. TIMP-2 inhibits all active MMPs, by contrast, it also regulates the MT1-MMP-dependent activation of pro-MMP2 (8,9). Thus, TIMP-2 has two different aspects of MMP-regulating activity. TIMP-2 also inhibits endothelial cell proliferation and angiogenesis independently from MMP regulating activity (10).

The present study focused on the highly conserved tryptophan residues in TIMP-2 and investigated whether they are important for their function.

Materials and methods

Cell culture

A human fibrosarcoma HT1080 cell line obtained from Japanese Cancer Research Resources Bank (Tsukuba, Japan) was cultured in DMEM supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin G, 100 mg/l kanamycin, 600 mg/l L-glutamine and 2.25 g/l NaHCO3 at 37°C in a humidified incubator with 5% CO2.

Construction of TIMP-2 expression plasmid and site-directed mutagenesis

The human TIMP-2 gene was amplified from the cDNA of HT1080 cells and subcloned into a pCI-neo vector (Promega Corporation, Madison, WI, USA). Certain tryptophan residues in TIMP-2 were substituted with alanine residues by PCR site-directed mutagenesis using overlap extension technique. The sequences of primers used for the mutagenesis were as follows: W133A forward, 5′-CTTCATCGT GCCCGCGGACACCCTGAGCACC-3′ and reverse, 5′-GGT GCTCAGGGTGTCCGCGGGCACGATGAAG-3′; W174A forward, 5′-GACGAGTGCCTCGCGATGGACTGGGTC-3′ and reverse, 5′-GACCCAGTCCATCGCGAGGCACTC GTC-3′; W177A forward, 5′-GCCTCTGGATGGACGCGG TCACAGAGAAG-3′ and reverse, 5′-CTTCTCTGTGACCGC GTCCATCCAGAGGC-3′; and W203A forward, 5′-CGGCTC CTGTGCGGCGTACCGCGGCGCGGCGC-3′ and reverse, 5′-GCGCCGCGCCGCGGTACGCCGCACAGGAGCCG-3′.

Establishment of TIMP-2-overexpressing stable cell lines

The permanent cell lines stably expressing wild-type (wt) and mutant TIMP-2-myc-his6 (T2-MH) were established by transfecting the vectors into HT1080 cells using Lipofectamine LTX (Life Technologies, Carlsbad, CA, USA) followed by G418 (Roche Diagnostics, Indianapolis, IN, USA) selection. The clone cells that expressed high levels of myc-his6-tagged wt TIMP-2 and TIMP-2 W133A, W174A, W177A and W203A were designated as HT1080-T2-MH, HT1080-T2-MH/W133A, HT1080-T2-MH/W174A, HT1080-T2-MH/W177A and HT1080-T2-MH/W203A cells, respectively. The cells transfected with pCI-neo were designated as HT1080-neo.

RNA isolation and semi-quantitative polymerase chain reaction (PCR) analysis

Total RNAs were extracted from cultured cells by using TRIzol reagent (Life Technologies). Reverse transcription was performed at 37°C for 120 min with a High Capacity cDNA Reverse Transcription kit (Life Technologies). The cDNA was used for PCR amplification with rTaq DNA polymerase (Takara Bio, Inc., Shiga, Japan). The number of PCR cycles for each product was determined following confirmation of the efficacy of amplification and having defined the linear primers used for semi-quantitative PCR. The number of cycles and annealing temperatures were as follows: Exogenous T2-MH forward, 5′-GGCGTTTTG CAATGCAGATGTAGTG-3′ and reverse, 5′-GTGATGGTGAT GATGCAGATCCTCTTCTGAGATGAG-3′ (25 cycles; 55°C); and GAPDH forward, 5′-TGAAGGTCGGAGTCAACG GATTTGGT-3′ and reverse, 5′-CATGTGGGCCATGAGGTC CACCAC-3′ (25 cycles; 55°C). PCR products were electrophoresed on 1% agarose gels, stained with ethidium bromide and visualized with a UV illuminator (Desktop Gel Imager SCOPE21; OPTIMA Inc., Tokyo, Japan).

Western blot analysis

Western blot analysis was performed as previously described with slight modifications (11). For detection of intracellular protein levels, cells were lysed with lysis buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% (w/v) SDS, 1% (v/v) Triton X-100, 1% (w/v) sodium deoxycholate and 1 mM PMSF] and centrifuged at 14,000 × g for 10 min. The protein concentrations of the supernatants were determined and secreted proteins were collected from conditioned media. Aliquots of the cell lysates with 6X sample buffer [350 mM Tris-HCl (pH 6.8), 30% glycerol, 0.012% bromophenol blue, 6% SDS and 30% 2-Mercaptoethanol] were subsequently boiled for 3 min and electrophoresed on SDS-polyacrylamide gels. Proteins were transferred to polyvinylidene difluoride membranes and immunoblotted with anti-c-myc (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) or anti-β-actin (Sigma-Aldrich, St Louis, MO, USA) antibodies. Detection was performed with enhanced chemiluminescence reagent (EMD Millipore Corporation, Billerica, MA, USA).

Immunofluorescence analysis

Immunofluorescence analysis was performed as previously described with slight modifications (12). The cells grown on cover slips were washed with phosphate-buffered saline (PBS), fixed with 4% para-formaldehyde and permeabilized with 0.1% Triton X-100 for 10 min. Following blocking with 2% bovine serum albumin, the cells were incubated with anti-c-myc (Santa Cruz Biotechnology, Inc. or Cell Signaling Technology, Inc., Beverly, MA, USA), anti-KDEL (StressGen Bioreagents, Victoria, BC, Canada) and anti-GRASP65 (Santa Cruz Biotechnology, Inc.) antibodies for 1 h. Alexa 488-conjugated anti-mouse and anti-rabbit IgG (Life Technologies) were used as the secondary antibodies. After washing three times with PBS, the cells were incubated with 2 μg/ml Hoechst 33258 (Wako Pure Chemical Industries, Ltd., Osaka, Japan) for 10 min to stain the nuclei. Then, the cells were washed three times with PBS and observed under a fluorescence microscope (EVOS FL Cell Imaging System; Life Technologies).

Results

Conserved tryptophan residues in TIMP-2 are important for its secretion

There are four tryptophan residues (Trp133, Trp174, Trp177 and Trp203) in human TIMP-2 and they are highly conserved in vertebrates, as shown in Fig. 1A. However, although three of these tryptophan residues (Trp133, Trp174 and Trp203) are conserved among human TIMP family proteins, one (Trp177) is unconserved, as shown in Fig. 1B. In order to demonstrate the importance of conserved tryptophan residues for TIMP-2 secretion, cell lines overexpressing C-terminus myc-his6 tagged wt TIMP-2 (T2-MH) or mutants replacing tryptophan residues to alanine residues (T2-MH/W133A, T2-MH/W174A, T2-MH/W177A and T2-MH/W203A) were established (Fig. 2A). Equal amounts of exogenous TIMP-2 mRNA in the stable cell lines were confirmed by semi-quantitative PCR analysis (Fig. 2B).

Figure 1

Schematic illustration of amino acid sequence homology among TIMP family proteins. (A) Conserved TIMP-2 sequences in Homo sapiens, Mus musculus, Xenopus laevis and Danio rerio, with tryptophan residues indicated in red. (B) Conserved sequences of TIMP family proteins, with tryptophan residues indicated in red. TIMP, tissue inhibitor of metalloproteinase; SP, single peptide.

Figure 2

Conserved tryptophan residues in TIMP-2 are important for its secretion. (A) HT1080-neo, HT1080-T2-MH, HT1080-T2-MH/W133A, HT1080-T2-MH/W174A, HT1080-T2-MH/W177A and HT1080-T2-MH/W203A cells were lysed and aliquots of the cell lysates were electrophoresed and immunoblotted with anti-c-myc or anti-β-actin antibodies. (B) Total RNAs were isolated from each cell line and exogenous TIMP-2 mRNA levels were analyzed by semi-quantitative polymerase chain reaction. (C) Each cell line was cultured in serum-free media for 24 h. Samples from the conditioned media and aliquots of the cell lysates were electrophoresed and immunoblotted with anti-c-myc antibody. CBB staining was used as a loading control. TIMP-2, tissue inhibitor of metalloproteinase-2; T2-MH, TIMP-2-myc-his6; IB, immunoblotting; CBB, Coomassie brilliant blue.

Since TIMPs are secreted and function in the extracellular space, the effect of the mutation of tryptophan residues on the secretion of TIMP-2 was first examined. The levels of secreted wt and W177A mutant in conditioned media were approximately the same, whereas the protein levels of secreted W133A, W174A and W203A mutants were significantly lower than those of the wt (Fig. 2C). These results indicated that conserved tryptophan residues are required for TIMP-2 secretion.

Conserved tryptophan residues in TIMP-2 are important for its endoplasmic reticulum (ER)-Golgi traffic

The majority of secretory proteins contain hydrophobic signal peptides that direct proteins to the ER and Golgi apparatus and, subsequently, to the extracellular space or plasma membrane through the ER-Golgi secretory pathway (13). To investigate whether the lower levels of secreted TIMP-2 mutated in conserved tryptophan residues was due to the inhibition of ER-Golgi transport, the effect of the mutation of conserved tryptophan residues on the intracellular localization of TIMP-2 was examined. Immunofluorescence analysis revealed that the wt and W177A mutant stained with anti-c-myc antibody were mainly localized in the Golgi apparatus (Fig. 3A), whereas the W133A, W174A and W203A mutants were mainly localized in the ER (Fig. 3B). These results indicated that the mutation in conserved tryptophan residues inhibited the ER-Golgi traffic of TIMP-2. Thus, conserved tryptophan residues of TIMP-2 are critical for transportation to the Golgi apparatus and subsequent secretion.

Figure 3

Role of conserved tryptophan residues of TIMP-2 on the intracellular localization. (A) HT1080-neo, HT1080-T2-MH, HT1080-T2-MH/W133A, HT1080-T2-MH/W174A, HT1080-T2-MH/W177A and HT1080-T2-MH/W203A cells were fixed and stained with Hoechst 33258 (nuclei; blue) and anti-c-myc (T2-MH; green) and anti-GRASP65 (Golgi apparatus; red) antibodies. (B) HT1080-neo, HT1080-T2-MH, HT1080-T2-MH/W133A, HT1080-T2-MH/W174A, HT1080-T2-MH/W177A and HT1080-T2-MH/W203A cells were fixed and stained with Hoechst 33258 (nuclei; blue) and anti-c-myc (T2-MH; red) and anti-KDEL (endoplasmic reticulum; green) antibodies. Cells were observed by fluorescence microscopy (scale bars, 25 μm). TIMP-2, tissue inhibitor of metalloproteinase-2; T2-MH, TIMP-2-myc-his6; wt, wild type.

Discussion

Previous studies have shown that TIMPs contain 12 conserved cysteine residues that are important for its structure (6). Since the conservation of the relative positions of these residues may support their function and structure, the present study focused on the conserved tryptophan residues of TIMP-2. The observations revealed that the conserved tryptophan residues of TIMP-2 are important in its ER-Golgi transport and subsequent secretion. Furthermore, the importance of conserved tryptophan residues in other family proteins (TIMP-1, -3 and -4) for their secretion was evaluated (data not shown). Besides three conserved tryptophan residues, TIMP-1 has no unconserved tryptophan residue, whereas TIMP-3 and -4 contain one unconserved tryptophan residue. Using HT1080 stable cell lines overexpressing mutant proteins, in which each tryptophan residue is replaced by alanine, the conserved tryptophan residues in TIMP-1, -3 and -4 were demonstrated to be essential for secretion, as in the case of TIMP-2. Thus, it was demonstrated that tryptophan residues conserved among TIMP family proteins are critical for the secretion of TIMP family proteins. However, the mechanisms underlying the inhibitory effect on ER-Golgi transport due to the mutation of conserved tryptophan residues remain unclear. One possible reason is the inhibition of the glycosylation of TIMP-2 by the mutation of tryptophan residues, since TIMP-2 contains a Trp-Xaa-Xaa-Trp (where Xaa represents any amino acid) sequence that is the consensus sequence for C-mannosylation (14) and Trp174 is a potential C-mannosylation site. In the current study, to examine whether TIMP-2 is C-mannosylated at Trp174, recombinant TIMP-2 protein was purified from conditioned medium of HT1080-TIMP-2-MH cells and purified TIMP-2 was analyzed by MALDI-TOF MS. However, no peak of fragments generated by C-mannosylation was observed, suggesting that C-mannosylation is not involved in the secretion of TIMP-2.

The majority of secretory proteins are transported from the ER to the Golgi apparatus by the membrane vesicles composed of a multisubunit protein complex, coat protein complex II (COP-II). In this process, cargo proteins are sorted by the Sec24 subunit of COP-II and are incorporated into COP-II vesicles for transportation from the ER to the Golgi apparatus (13). It is likely that the mutation of tryptophan to alanine changes the conformation of TIMPs and causes abnormalities of recognition by the proteins involved in the step of ER-Golgi transport.

Increasing evidence indicates that the TIMP family of proteins are involved in the suppression of tumor invasion and metastasis in numerous types of human cancer by regulating ECM turnover (2–4). Therefore, the observations of the current study provide a new insight into the TIMP family of proteins and are likely to contribute to understanding the mechanisms of cancer metastasis.

Acknowledgements

The current study was supported in part by grants from the Grants-in-Aid for Scientific Research (B) and Grant-in-Aid for Young Scientists (Start-up) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.

References

1 

Yoon SO, Park SJ, Yun CH and Chung AS: Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 36:128–137. 2003. View Article : Google Scholar : PubMed/NCBI

2 

Brew K and Nagase H: The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 1803:55–71. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Bloomston M, Shafii A, Zervos EE and Rosemurgy AS: TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res. 102:39–44. 2002. View Article : Google Scholar : PubMed/NCBI

4 

Bourboulia D and Stetler-Stevenson WG: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Brew K, Dinakarpandian D and Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 1477:267–283. 2000. View Article : Google Scholar : PubMed/NCBI

6 

Williamson RA, Marston FA, Angal S, Koklitis P, Panico M, Morris HR, Carne AF, Smith BJ, Harris TJ and Freedman RB: Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem J. 268:267–274. 1990.PubMed/NCBI

7 

Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 69:562–573. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N, Aoki T and Seiki M: Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J. 20:4782–4793. 2001. View Article : Google Scholar : PubMed/NCBI

9 

Hernandez-Barrantes S, Toth M, Bernardo MM, Yurkova M, Gervasi DC, Raz Y, Sang QA and Fridman R: Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem. 275:12080–12089. 2000. View Article : Google Scholar : PubMed/NCBI

10 

Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY and Stetler-Stevenson WG: TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. 114:171–180. 2003. View Article : Google Scholar : PubMed/NCBI

11 

Sasazawa Y, Kanagaki S, Tashiro E, Nogawa T, Muroi M, Kondoh Y, Osada H and Imoto M: Xanthohumol impairs autophagosome maturation through direct inhibition of valosin-containing protein. ACS Chem Biol. 7:892–900. 2012. View Article : Google Scholar

12 

Niwa Y, Suzuki T, Dohmae N, Umezawa K and Simizu S: Determination of cathepsin V activity and intracellular trafficking by N-glycosylation. FEBS Lett. 586:3601–3607. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Lee MC, Miller EA, Goldberg J, Orci L and Schekman R: Bi-directional protein transport between the ER and Golgi. Annu Rev Cell Dev Biol. 20:87–123. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Krieg J, Hartmann S, Vicentini A, Glasner W, Hess D and Hofsteenge J: Recognition signal for C-mannosylation of Trp-7 in RNase 2 consists of sequence Trp-x-x-Trp. Mol Biol Cell. 9:301–309. 1998. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Ukaji T, Sasazawa Y, Umezawa K and Simizu S: Involvement of conserved tryptophan residues for secretion of TIMP‑2. Oncol Lett 7: 631-634, 2014.
APA
Ukaji, T., Sasazawa, Y., Umezawa, K., & Simizu, S. (2014). Involvement of conserved tryptophan residues for secretion of TIMP‑2. Oncology Letters, 7, 631-634. https://doi.org/10.3892/ol.2013.1771
MLA
Ukaji, T., Sasazawa, Y., Umezawa, K., Simizu, S."Involvement of conserved tryptophan residues for secretion of TIMP‑2". Oncology Letters 7.3 (2014): 631-634.
Chicago
Ukaji, T., Sasazawa, Y., Umezawa, K., Simizu, S."Involvement of conserved tryptophan residues for secretion of TIMP‑2". Oncology Letters 7, no. 3 (2014): 631-634. https://doi.org/10.3892/ol.2013.1771
Copy and paste a formatted citation
x
Spandidos Publications style
Ukaji T, Sasazawa Y, Umezawa K and Simizu S: Involvement of conserved tryptophan residues for secretion of TIMP‑2. Oncol Lett 7: 631-634, 2014.
APA
Ukaji, T., Sasazawa, Y., Umezawa, K., & Simizu, S. (2014). Involvement of conserved tryptophan residues for secretion of TIMP‑2. Oncology Letters, 7, 631-634. https://doi.org/10.3892/ol.2013.1771
MLA
Ukaji, T., Sasazawa, Y., Umezawa, K., Simizu, S."Involvement of conserved tryptophan residues for secretion of TIMP‑2". Oncology Letters 7.3 (2014): 631-634.
Chicago
Ukaji, T., Sasazawa, Y., Umezawa, K., Simizu, S."Involvement of conserved tryptophan residues for secretion of TIMP‑2". Oncology Letters 7, no. 3 (2014): 631-634. https://doi.org/10.3892/ol.2013.1771
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team